Figure 10.

ZLc002 synergizes with paclitaxel in HeyA8 cells to reduce ovarian tumor cell line viability. Dose–response matrix delineating the effect of (a) ZLc002 and (b) paclitaxel in HeyA8 cells. Rel EC95, Relative EC₉₅ = 0 µM, reflects absence of inhibition of HeyA8 tumor cell viability by ZLc002; Abs EC₅₀, Absolute EC₅₀ = 10.2 nM, reflects efficacy of paclitaxel in reducing HeyA8 tumor cell viability by 50% of maximum. (c–d) Single-agent and combination responses determined by an MTT viability assay in 4T1 cells. The landscape of the combination responses for ZLc002 and paclitaxel based on the (E) Bliss model, (F) Loewe model, and (G) highest single agent (HSA) model. Each model supports synergism of the combination of ZLc002 with paclitaxel in reducing tumor cell line viability. (n = 3 experiments). HSA: highest single agent.